Sabra Healthcare REIT, the Real Estate sector company, was revisited by a Wall Street analyst today. Analyst Juan C. Sanabria from BMO Capital maintained a Hold rating on the stock and has a $22.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Juan C. Sanabria has given his Hold rating due to a combination of factors tied to Sabra Healthcare REIT’s operating results and outlook. The company’s 4Q25 funds available for distribution matched expectations once SHOP-related capital expenditures are excluded, and same-store NOI in the SHOP portfolio showed strong double-digit growth with improving occupancy, supporting a slightly better-than-expected FAD outlook.
At the same time, normalized FFO modestly missed consensus, and 2025 FFO guidance was set below both Street and BMO forecasts, tempering the otherwise solid operating momentum. While investment activity is accelerating and largely pre-funded, Sanabria is watching the upcoming RCA loan maturity and the financial condition of the operator, which together introduce enough uncertainty to justify maintaining a neutral, Hold stance on the shares rather than turning more positive.